Biotech in Brasil
Cluster Minas Gerais
V Seminário de Negócios
Biotechnology | Brasil
Biotechnology | Brasil
The Brazil stands out, along with Russia, India, China and South Africa, as a
major emerging country of the first decade of the 21st century.
Since 1990, the country has experienced steady GDP growth of around 3%
per year, with a slight dip in 2012, when growth was 0.9%.
Several government institutions such as BNDES, FINEP and others have
supported and invested in Brazil.
The Ministry of Science, Technology and Innovation and the Ministry of
Development, Industry and Foreign Trade have been very active in
implementing policies of national innovation.
Biotechnology | Brasil
Biotechnology | Minas Gerais
Contexto
Econômico
Economic Context
Fonte: PBH
Biotechnology | Minas Gerais
Minas Gerais is the second largest economy in the country, with
growth rates above the national average.
The Government of Minas prioritizes investments in the
production and development of Minas Gerais Technology Park - making the
state one of the most innovative Latin America.
Government of Minas put the sector of biotechnology and life sciences as
one of the main axes of work and investment.
+ 200 manufacturing Biotech and Life Sciences companies.
Biotechnology | Minas Gerais
Technological Incubators: Inova (UFMG), Habitat (Biominas), INCIT,...;
Very good Universities: UFMG, Ciências Médicas, PUC Minas.
Research Centers (EMBRAPA, CETEC, FUNED, FIOCRUZ/RR).
Ezequiel Dias Foundation - FUNED
EZEQUIEL DIAS FOUNDATION (FUNED)
State Institution linked to Minas Gerais Health Department
FUNED is aligning SUS (National Health System) policies - Domestic
production of drugs currently imported by the government.
FUNED is a major supplier
for Ministry of Health and
MG for Pharma Medicines
and Serum (snakes, tetanus,
etc).
Policies for foreign investments
Ranking
Incentive for investments
Policies for foreign capital
Source: Unidade de Inteligência da Economist, Veja Abril (2012)
AMBIOTEC
Minas Gerais Bioindustry Association
The Governance of Biotech Cluster
AMBIOTEC is a Private and non-profit
Association;
Located in Technological Park BHTEC;
 Created in 2010 by biotech companies;
 more than 40 members manufacturers
of products and services in the areas of
human, animal and environment;
Generate annual turnover of US$ 700
million (more than 2 billion Reais).
Technologial Park Belo Horizonte - BHTEC
Business Environment
Business
Environment
Fonte: Belotur
Cluster: Products and Services
HUMAN HEALTH
 Molecular Diagnostics;
 Diagnostic kits and reagents for clinical analysis;
 Bone and tissue reconstruction;
 Injectable drugs and pharmaceuticals;
 Reagents for rapid tests;
 Production of synthetic antibodies;
Proccess optimization – automation equipments;
 Medical devices;
 Laboratory Control.
Cluster: Products and Services
ANIMAL HEALTH AND AGRIBUSINESS
 Animal genetics diagnostics by DNA;
 Animal and plant genetic breeding;
 Injectable medicine.
ENVIRONMENT
Consulting services;
Microbiological and physico-chemical tests
Medical Devices
Companies at the Belo Horizonte area:
Companies certified and registered at ANVISA
Opportunity in the Brazilian and South America Market
The Summary
• Entrepreneurs background/career
• Company history
• Company profile
• Products
• Sales activities
• Growing strategy
• Commercial projections
• Strengths / Company organization / Our offer
• Shareholders and strategic alliances
• Contacts
Background/Career
Mr. Denilson Laudares Rodrigues
• Electrical Engineering (1993)
Pontifical Catholic University of MG – PUC Minas
• MSc Mechatronics (1997)
Aeronautics Technological Institute – ITA
• Ph.D. Computer Science (2002)
Federal University of MG – UFMG
University of Pennsylvania – UPENN – U.S.
• Part-time professor at PUC Minas
• Founder and CEO of Celer Biotecnologia S/A
Background/Career
Mr. Andreas Flugs
• Industrial Engineering and Management – MSc
Ilmenau University of Technology – Germany (1998)
• CEO of BERATA GmbH, Altran Affiliate, Munich,
Germany, (2000-2005)
• Senior Consultant of BeOne München GmbH, Munich,
Germany, (2005-2008)
• COO of CELER, Brazil (2009)
Background/Career
Mr. Rafael Vilarinhos
• Regional Sales Manager
BIOBRAS (2002-2008)
• National Sales Manager
PRODIMOL / ALERE (2008-2012)
• Business Administration – Unopar – Brazil (2012)
• CCO of CELER, Brazil (2012)
The Company
MISSION
Provide high technology in customizable solutions to
optimize process to the heath sector.
VISION
Become the leading reference in the Latin America market as
a supplier of innovative solutions to improve the human
health.
History Timeline
AFE and Initial
Registrations
Microplate
Reader and
Washer;
Tax Benefits
2009
2011
2008
Invested by
CRIATEC
2010
Semiautomatic
Biochemistry
New Partner and
Business Model
2012
GMP (CBPF) for
instruments
manufacturing
2013
Portfolio expansion
and new
opportunities
2014
New registers;
GMP for
Consumables;
Importer and
Distributer
2015
The Company
• Develops and produces instruments for
automation in clinical diagnosis.
• Multi skilled technical staff.
• Close connections with universities,
research centers and companies in clinical
diagnostics.
• Partner of BNDES (CRIATEC Fund)
• Local regulations – ANVISA CBPF (GMP).
Our distribution network
Distribution network
Celer has a wide network of
Distributors that covers all
regions of Brazil.
This
Network
includes
34
Distributors witch are attending
the private market as well as the
public sector and two commercial
representants to serve the North
and Northeast.
Beside of the distribution network
CELER participates direct on
public tenders.
Strategy
Current portfolio
1
New partner
Production “in
house”
BS, EE, EV
Other possibilities
FINAL CLIENT
“Laboratories”
BA, EA, QL, ..
Lab. Research
Netw.
Of Dist.
Lab. diagnostic
Re-Sales
2
National
Partner
OEM
Service for
technical
assistant
3
Commerce of CELER
International
Partner
Equip. +
Reagents
Agents
Export
Distributors
CELER`s Strengths
• “CBPF” ANVISA certificated production system – Certification of
good manufacturing practices.
• “BDNDES payment card”
Payments of national products/instruments with up to 48 rates.
CELER is receiving the payment on time.
• “NBC T19,41” CELER is audited once per year for good
governance practices.
• CELER received public investment and is, because of this, always
in favor of public institutions, specific in registration of products
within ANVISA.
• With the law nr. 12.349, CELER has a major competitiveness to
gain public tenders while the state has to prefer national products
for public tenders.
Our offer
• CELER offers you OEM production at the best quality level and the
Implementation with a strong R&D team (PhD and Masters).
• CELER operate for you a strong distribution network to serve the
market of BRAZIL and SOUTH AMERICA.
• CELER is open for direct or indirect business participation.
• Familiarity with management of equipment/instruments productive
processes for greater degree of complexity.
• Investment Fund Governmental (BNDES) Partnership, which
provides differentiated treatment in all levels of government
processes and opportunities for future investments.
Strategic Alliances
Contacts
Denilson Laudares Rodrigues
[email protected]
+55 31 9302-1082
Andreas Flugs
[email protected]
+55 31 8429-2868
Rafael Vilarinhos
[email protected]
+55 31 9165-1308
www.celer.ind.br
Rua Padre Eustáquio, 1133 subloja 11
Belo Horizonte – MG – ZIP 30710.580 – Brazil
Phone +55 31 3413-0814
Thank you!
Denilson Laudares Rodrigues
Conselheiro AMBIOTEC
[email protected]
www.ambiotec.org.br
+55 31 3401-1125